In addition, favorable survival outcomes in ARID1A mutant patients when receiving ICB treatment were also revealed in a pan-cancer study [16], but merely 10 EC samples with the ARID1A mutation were included, not sufficient to demonstrate the survival difference. Here, ARID1A is linked to cancer.